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A B S T R A C T
Purpose: The study aims to quantify the expected impacts of different cancers through multiplying the
incidence rate by loss-of-QALE (quality-adjusted life expectancy), with QALY (quality-adjusted life year)
as the common unit, to aid prevention policy decisions.
Methods: 464,722 patients with pathologically veriﬁed cancer registered in the Taiwan Cancer Registry
during 1998–2009 were used to estimate lifetime survival through Kaplan–Meier estimation combined
with a semi-parametric method. A convenience sample for measuring the utility value with EQ-5D was
conducted with 11,453 cancer patients, with the results then multiplied by the survival functions to
estimate QALE. The loss-of-QALE was calculated by subtracting the QALE of each cancer cohort from the
life expectancy of the corresponding age- and gender-matched reference population. The cumulative
incidence rates from age 20 to 79 (CIR20–79) were calculated to estimate the lifetime risk of cancer for
each organ-system.
Results: Liver and lung cancer were found the highest expected lifetime health impacts in males and
females, or expected lifetime losses of 0.97 and 0.41 QALYs that could be averted, respectively. While the
priority changes for prevention based on expected health impacts were slightly different for females
based on standardized mortality rates, those of males involve a broader spectrum, including oral,
colorectal, esophageal and stomach cancer.
Conclusion: The integration of incidence rate with loss-of-QALE could be used to represent the expected
losses that could be averted by prevention, which may be useful in prioritizing strategies for cancer
control.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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jou r nal h o mep age: w ww.c an cer ep idem io log y.n et1. Introduction
While applications of epidemiologic methods to health policy
decisions were once popular before the 19th century, they have
become less widely used since the beginning of the second half of
the 20th century. Although estimates of standardized mortality
rates can still provide useful information on the impacts of diseases
or technologies, which can then aid health policy decision, such* Corresponding author at: Department of Public Health, National Cheng Kung
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3.0/).comparisons for different illnesses have become less efﬁcient,
especially because for most cancers patients usually survive for
more than 5–10 years, and thus one must wait for a long period of
time for mortality to occur [1–6]. The current coding of one
underlying cause of death might also underestimate the impact of
other causes, including cancer. At the same time, the sustainability
of current healthcare systems has become questionable under the
ﬁnancial pressures of an aging population and development of new
technologies [7]. From 1971 to 2012, the number of cancer
survivors in the United States increased from 3.0 million to
13.4 million, representing 4.6% of the population [8,9]. As the
population of cancer survivors increases, the economic impact of
cancer for patients, caregivers, employers, the health-care system
and society overall is expected to grow [10,11]. There is thus a neede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. Estimation of loss-of-QALE (quality-adjusted life expectancy): the dashed
line represents the QALE of male patients with colorectal cancer, while the solid line
represents the QALE of corresponding age and sex-matched referents. The area
between solid and dashed lines would be the loss-of-QALE, or 5.19 QALY (quality-
adjusted life years).
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making policy decisions.
In clinical medicine, QALY (quality-adjusted life years) is a
measure that incorporates both quality of life and length of survival
into one common unit, and this has been widely applied in cost-
utility and/or cost-effectiveness analysis over the last few decades
[12–14]. Recently, the authors of this study have developed
estimates of the expected years of life lost and loss-of-QALE that
quantify the consequences of illness with life-year and QALY,
respectively, which make possible direct comparisons of prevention
with clinical care [1–4,15] if incidence rates can also be incorporated
together [16]. It may thus be possible to quantify both incidence
rates and how much utility is lost from developing a speciﬁc illness,
rather than simply making policy decisions based on mortality rates.
Unfortunately, randomized controlled trials are generally
expensive, and the ﬁnancial costs for those focused on prevention
are even higher because of the low occurrence rates of most
diseases [17,18]. Therefore, we attempted to use the big data and/
or databases of electronic medical records available in Taiwan to
integrate the likelihood of an event, or incidence rate and
consequence of an event, or loss-of-QALE, to estimate the lifetime
health impacts of major cancers to aid prevention policy
decisions, and further compare the results of this with the
standardized mortality rates in order to decide priorities for
cancer prevention efforts. In other words, we quantiﬁed the
lifetime risk (or, cumulative incidence rate for age 20–79) and
then multiplied this by the loss-of-QALE to estimate the health
impacts for different cancers, and compared the results with the
related standardized mortality rates.
2. Method
2.1. Study population and datasets
The study commenced after gaining approval of the Institu-
tional Review Board of the National Cheng Kung University
Hospital (NCKUH, IRB number: ER-102-034). Written informed
consent was obtained from every interviewed cancer patient. A
total of 464,722 patients with pathologically diagnosed cancer
aged 20–79 years at diagnosis were abstracted and veriﬁed from
the Taiwan Cancer Registry for 1998–2009, which contains data on
the patients’ demographics, date of diagnosis, cancer site, histology
and vital status, and followed up until 2011 [19]. The identiﬁcation
numbers of all individuals were encrypted to protect their privacy.
The nine major cancers included lung (ICD-9-CM code: 162),
esophagus (ICD-9-CM code: 150), liver (ICD-9-CM code: 155),
stomach (ICD-9-CM code: 151), colorectum (ICD-9-CM code: 153–
154), oral (ICD-9-CM code: 140–141), nasopharynx (ICD-9-CM
code: 147), cervix (ICD-9-CM code: 180), and breast (ICD-9-CM
code: 174).
2.2. Survival analysis and extrapolation to estimate life expectancy for
different cancers
All of the above patients were linked to the Taiwan Mortality
Registry during 1998–2011 to obtain their survival functions via
the Kaplan–Meier estimation method up to the end of the follow-
up period. These were further extrapolated to lifetime based on a
semi-parametric method using the age- and sex-matched referents
simulated from the life tables of the Taiwan Vital Statistics, which
only requires an assumption of constant excess hazards after the
end of follow-up [20,21]. The computation of these estimates were
carried out using iSQoL software [22]. Detailed methods
and mathematical proofs are described in our previous studies
[1–4,20,21].2.3. Measurements of quality of life (QOL) via EQ-5D for estimation of
quality-adjusted life expectancies (QALE) and loss-of-QALE
To estimate the utility value of QOL for cancer patients at
different duration-to-dates (namely, from diagnosis of disease up
to the date of interview), we recruited a convenient, cross-sectional
sample with 11,453 measurements aged 20–79 years at diagnosis
between 2011 and 2014 at the Oncology Center of NCKUH. Patients
were not included if they had disturbances in consciousness,
moderate to severe dementia or aphasia, or an inability to
communicate with research assistants. We assessed their QOL
by administering the Taiwanese version of EQ-5D [23] through
direct face-to-face interviews. EQ-5D is a preference-based,
generic instrument [24,25] that provides a utility value based
on survey carried out in Taiwan [26]. A kernel-type smoothing
method (using a moving average of the nearby 10%) was performed
to estimate the mean QOL across time [27,28]. The lifetime survival
probabilities over the course of a cancer were multiplied (or
adjusted) with the QOL utility values to obtain a quality-adjusted
survival curve. The loss-of-QALE for these patients was calculated
by subtracting the QALE of cancer patients from the QALE of the
age- and gender- matched referents simulated from the hazard
functions of vital statistics with the EQ-5D utility values borrowed
from those of the 2009 National Health Interview Survey in
Taiwan, as illustrated in Fig. 1 with colorectal cancer as an
example.
2.4. Estimation of cumulative incidence rates (CIR) of major cancers
We used data from the Catastrophic Illnesses Registry database
of Taiwan for the period 2008–2010 [29] to calculate the incidence
rates of major cancers. The CIR was calculated from age 20 to 79
(CIR20–79) to estimate the lifetime risk of a speciﬁc cancer, as
follows
CIR ¼ 1  exp 
X
i
ðIRiÞðDtiÞ
h i
where IRi represents the age-speciﬁc incidence rate and Dti
indicates the range of each age stratum.
2.5. Expected health impacts for cancer
The health impact of cancer at each organ-system was
estimated by multiplying the CIR with loss-of-QALE of nine major
cancers. We ﬁrst estimated the lifetime risks by CIR20–79, or age
from 20 to 79, followed by CIR20–44, and CIR45–64, and CIR65–79, and
Table 1
Comparison of frequency distributions of cancer patients registered in the Cancer
Registry of Taiwan and a cross-sectional sample at oncology clinics.
Cancer
patients (1998–2009)
Cross-sectional
sample (2011–2014)
Liver, no. case 91,747 1612
Sex (% male) 67,461 (73.5) 1182 (73.3)
Mean age (years, SD) 60.8 (11.8) 58.7 (10.4)
Lung, no. case 74,720 3073
Sex (% male)* 49,598 (66.4) 1567 (51)
Mean age (years, SD)* 64.4 (11.0) 60.9 (10.3)
Oral, no. case 38,662 1559
Sex (% male) 35,222 (91.1) 1445 (92.7)
Mean age (years, SD) 52 (11.4) 52 (9.2)
Colorectum, No. case 89,276 2763
Sex (% male) 51,190 (57.3) 1552 (56.2)
Mean age (years, SD) 62 (12.2) 60 (11.3)
Esophagus, no. case 15,924 284
Sex (% male) 14,931 (93.7) 266 (93.7)
Mean age (years, SD) 58 (11.2) 53.4 (9.1)
Stomach, no. case 35,720 336
Sex (% male) 22,978 (64.3) 198 (58.9)
Mean age (years, SD) 62.8 (12.5) 58.3 (12.3)
Nasopharynx, no. case 17,118 284
Sex (% male) 12,750 (74.5) 214 (75.3)
Mean age (years, SD) 49.6 (12.4) 48 (10.9)
Cervix, no. case 24,525 689
Mean age (years, SD) 53.9 (12.8) 50.1 (10)
Female breast, no. case 77,030 991
Mean age (years, SD) 50.9 (11.2) 48.7 (9.5)
* p < 0.05.
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loss-of-QALE within different age ranges.
2.6. Validation of the extrapolation method and sensitivity analysis
for loss-of-QALE
To show that our extrapolation method is valid, we selected
sub-cohorts of cancer patients between 1998 and 2004,
extrapolated these results to the end of 2011, and compared
the extrapolated results with the Kaplan–Meier (K–M) estimates
of the actual 14 years of follow-up. Assuming that the K–MTable 2
Comparison of expected lifetime impacts and standardized mortality rates adjusted by 
expected lifetime risk (CIR20–79)
a, loss-of-QALE (quality-adjusted life expectancy) unde
Sites of
cancer
Gender 2008–2010
(CIR20–79)
a (%)
Loss-of-QALE Loss-of-QALE
under lifetime risk
Liver Male 6.80 14.22 (0.03) 0.97 
Female 3.12 11.44 (0.07) 0.36 
Lung Male 6.05 11.66 (0.03) 0.71 
Female 3.15 13.11 (0.05) 0.41 
Oral Male 2.99 13.54 (0.12) 0.40 
Female 0.38 5.07 (0.51) 0.02 
Colorectum Male 6.30 5.19 (0.08) 0.33 
Female 4.36 5 (0.19) 0.22 
Esophagus Male 1.55 16.69 (0.06) 0.26 
Female 0.12 11.41 (0.78) 0.01 
Stomach Male 2.08 8.26 (0.16) 0.17 
Female 1.13 8.14 (0.19) 0.09 
Nasopharynx Male 0.88 13.75 (0.27) 0.12 
Female 0.29 11.54 (1.67) 0.03 
Female breast Female 6.52 5.22 (0.16) 0.34 
Cervix Female 1.37 3.17 (0.26) 0.04 
a CIR20–79, cumulative incidence rates from age 20 to 79.
b Cited from: https://cris.hpa.gov.tw/pagepub/Home.aspx?itemNo=cr.q.50.estimates are the gold standard, this study calculated the relative
biases for sub-cohorts with different cancers. The relative bias
(RB) is deﬁned as follows: RB = (estimate from extrapolation  K–
M estimate)/K–M estimate. In addition, we applied a sensitivity
analysis by assuming a uniform utility value of 1 for referents to
test if the ﬁnal conclusions of decision making are affected.
2.7. Other statistical analysis
The differences in the frequency distributions of cancer patients
between the cohort and cross-sectional samples at clinics were
tested with the chi-squared and two-sample t test, with
p < 0.05 regarded as signiﬁcant. The analysis was carried out
using SAS software (ver. 9.4). The standardized mortality rates
were calculated by adjusting the 2000 world standard population
for nine major cancers for different age periods with the age
speciﬁc cancer rates of Taiwan for the period 2008–2010, stratiﬁed
by gender [30].
3. Results
The basic demographic details of the cancer patients are
categorized by cancer sites in Table 1, which shows that the sex
distributions and mean ages at diagnosis of the cross-sectional
sample interviewed at the Oncology Center were similar to those in
the national data, except for lung cancer.
The average estimated loss-of-QALE were the highest for
esophageal cancer in males (16.69 QALYs) and lung cancer in
females (13.11 QALYs) followed by other cancers, while those of
male colorectal cancer and female cervical cancer had the lowest
estimates, at 5.19 and 3.17 QALYs, respectively (Table 2). After
multiplication with the incidence rates in Taiwan for the speciﬁc
cancer sites during 2008–2010, we found the highest expected
health impacts in males and females were liver and lung cancer,
with expected losses of 0.97 and 0.41 QALYs, respectively. As
summarized in Fig. 2, the priorities for prevention based on
expected health impacts are different from those based on
standardized mortality rates. While the priority changes in females
may be less affected except breast and colorectal cancers, those of
males involve a broader spectrum, including oral, colorectal,2000 world standard population for major cancers in Taiwan stratiﬁed by gender:
r unit of QALY (quality-adjusted life year).
Loss-of-QALE
(with referents’
utility as 1)
Loss-of-QALE under
lifetime risk
(with referents’ utility as 1)
2008–2010 standardized
mortality rates20–79
b
17.2 (0.04) 1.17 37.53  105
16.01 (0.07) 0.50 14.33  105
14.29 (0.03) 0.86 35.22  105
18.14 (0.04) 0.57 16.49  105
16.68 (0.1) 0.50 14.56  105
10.68 (0.53) 0.04 0.96  105
8.05 (0.08) 0.51 17.04  105
10.1 (0.16) 0.44 11.84  105
19.64 (0.07) 0.30 9.35  105
16.39 (0.66) 0.02 –
11.05 (0.15) 0.23 9.49  105
13.33 (0.19) 0.15 4.98  105
17.1 (0.31) 0.15 3.73  105
17.28 (1.49) 0.05 –
10.8 (0.16) 0.70 10.61  105
8.76 (0.24) 0.12 4.39  105
Fig. 2. Comparison of priority ratings for cancer prevention policy decisions between lifetime expected loss-of-QALE (quality-adjusted life expectancy) using the QALY
(quality-adjusted life years) as the common unit and standardized mortality rate adjusted for the 2000 world standard population stratiﬁed by gender.
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trends remained unchanged for the age groups of 45–64 after
stratiﬁcation. Lung cancer became the leading expected loss of
0.272 QALYs in the age group of 65–79 (Table 3).
The results of the validation of the extrapolation method for
estimates of survival for each cancer subcohort showed that all the
relative biases were less than 6.82%, despite the high censoring
rates (more than 80% for breast cancer), as summarized in the
Appendix 1. We expect that the possible bias would be even less
after 14 years of follow-up, because the life expectancy for each
cancer was usually below 15 years, except breast and cervical
cancer. If we assume a uniform utility value of one for referents in
the sensitivity analysis of loss-of-QALE, the priority setting for
prevention based on expected health impacts would be quite
different, with breast cancer becoming the top priority for cancer
control in females (Table 2).4. Discussion
This study is the ﬁrst that integrates incidence rates with loss-
of-QALE to estimate the health impacts and cancer risks to aid
cancer prevention policy decisions using QALY (quality-adjusted
life years) as the common unit. The results show that liver and lung
cancer had the highest expected health impacts in males and
females, or expected losses of 0.97 and 0.41 QALY, respectively. The
priorities for prevention based on expected health impacts are
different from those based on standardized mortality rates, with
oral, colorectal, esophageal and stomach cancer becoming the third
to sixth priority in cancer control for males (Table 2 and Fig. 2).
However, we must carefully examine the accuracy of our estimates
before making further inferences. First, since we only included
patients with the nine cancers veriﬁed with histopathological
evidence (except liver cancer) [31], the diagnoses were all valid.
Table 3
Estimation of expected risk, loss-of-QALE (quality-adjusted life expectancy) for an average case and expected loss-of-QALE for different major cancers stratiﬁed by age
periods.
Sites of cancer 2008–2010
(CIR20–44)
Loss-of-QALE
(20–44 years)
Expected loss-of-
QALE for
CIR20–44
2008–2010
(CIR45–64)
Loss-
of-QALE
(45–64 years)
Expected loss-
of-QALE for
CIR45–64
2008–2010
(CIR65–79)
Loss-of-
QALE
(65–79 years)
Expected loss-
of-QALE for
CIR65–79
Liver 0.0020 28.31 (0.14) 0.057 0.0142 17.21 (0.05) 0.244 0.0322 8.15 (0.04) 0.262
Lung 0.0011 29.53 (0.17) 0.032 0.0104 17.85 (0.05) 0.186 0.0326 8.34 (0.03) 0.272
Oral 0.0027 21.42 (0.29) 0.058 0.0086 12.91 (0.12) 0.111 0.0057 5.04 (0.14) 0.029
Colorectum 0.0021 16.03 (0.33) 0.034 0.0143 7.33 (0.12) 0.0143 0.0355 3.27 (0.07) 0.116
Esophagus 0.0006 29.3 (0.21) 0.018 0.0039 19.33 (0.09) 0.075 0.0037 8.34 (0.07) 0.031
Stomach 0.0006 21.59 (0.54) 0.013 0.0046 11.42 (0.12) 0.053 0.0147 5.69 (0.2) 0.084
Nasopharynx 0.0014 18.08 (0.87) 0.025 0.0027 12.62 (0.44) 0.034 0.0017 6.42 (0.38) 0.011
Female breast 0.0118 13.49 (0.44) 0.159 0.0352 4.98 (0.19) 0.175 0.0211 0.92 (0.44) 0.019
Cervix 0.0019 5.22 (0.23) 0.010 0.0059 5.82 (0.32) 0.034 0.0060 2.42 (0.57) 0.015
CIR, cumulative incidence rates.
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validated assumption of ‘‘constant excess hazard’’ after the end of
follow-up, which can be obtained by showing a straight line after
taking the logit transform of the survival ratio between the index
and age- and gender-matched referents [20,21]. In addition, since
our validation study of this method showed that the relative biases
were all below 6.8% after seven years of follow-up, it is reasonable
to assume that those of the estimation of life expectancies based on
14 years of follow-up would be even smaller. Third, we collected
the QOL measure using the EQ-5D from all patients attending the
oncology clinic of NCKUH, and obtained their utility values at
different time points after diagnosis to integrate with the survival
function at time t. In total we excluded approximately 1% of the
invited patients who were unable to communicate with research
assistants, plus 9% who refused to be interviewed, and the gender
and age distributions at diagnosis seemed similar to the national
data (Table 1). Therefore, our convenience samples might not be
biased too much, or at least are more accurate than simply making
inferences based on the mean values. Finally, CIR is an indicator
that is inherently standardized for the speciﬁed age period, and
there is no need to invoke any outside weights for comparison. In
addition, everyone’s QALY would be the same across different
illnesses and technologies, and could also be directly compared
with clinical care services [32]. The combination of these two
indicators would thus be more efﬁcient in quantifying the loss of
health after the occurrence of a speciﬁc illness. We thus tentatively
conclude that our results are relatively accurate and useful for
assisting policy decisions related to cancer prevention.
Based on the above analysis, oral and esophageal cancer became
the third and ﬁfth priority in cancer control for males followed by
colorectal and stomach cancer, especially for the age group of 45–
64, owing to its high loss-of-QALE; breast cancer became the third
priority for females followed by colorectal cancer, because of its
high CIR and loss-of-QALE. Had we assumed a uniform utility value
of 1 for the referents simulated from the general population, the
priority for prevention based on expected health impacts would
have been quite different, with breast cancer becoming the top
priority for cancer control in females because of their long
survivorship (Table 2). Because cancer patients may die of other
causes, the health effects attributed to cancer would be under-
estimated based on standardized mortality rate. In the U.S., an
estimated 64% of cancer survivors live for more than ﬁve years
after their diagnosis [33], and this usually requires continual
monitoring with regard to recurrence and long-term care for the
late effects of cancer [11,33], issues that must be addressed when
developing of cancer control policies. Therefore, counting the
potential savings with regard to loss-of-QALE, costs of lifetime
healthcare and long term care, and productivity loss for society
[34] when estimating the total health impact would be more
comprehensive and efﬁcient than considering the standardizedmortality rate or CIR alone, and it would be better if future
decisions cancer prevention policies would take all these potential
impacts into consideration.
5. Limitations
Our study has following limitations: ﬁrst, the lifetime
extrapolation is based on current and prior experiences, especially
the national life tables. However, such an ex post approach could
easily underestimate the actual survival of future cancer popula-
tions, because of the development and adoption of newer
technologies for cancer care. Therefore, our estimation of the
lifetime survival of cancer patients may be a conservative one,
while the loss-of-QALE and lifetime health impacts might be
overestimated. Second, during the lifetime extrapolation of the
QOL function, it was assumed that the patients continued to stay at
the same level of QOL as near the end of follow-up. This
assumption could have resulted in an overestimation, because
the real QOL might gradually decline as the patient ages [35]. Third,
as most of interviewed subjects were recruited from clinics, their
general conditions were probably better than those conﬁned at
home or institutions, which might have led to over-estimating the
QOL and under-estimating the prevention effects.
6. Conclusion
The integration of incidence rates with loss-of-QALE could be
used to represent the expected losses that could be averted by
prevention. This estimate can become a summary index of cost
effectiveness for cancer prevention, and may be useful in
prioritizing strategies for cancer control after considering other
related parameters.
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11.03 (0.03) 10.54 (0.01) 4.39
9.96 (0.04) 10.01 (0.02) 0.51References
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